Payment overview · 2025
General Payments
$3,500.67
149 reported records · 24 companies
Healthcare provider profile · identity verified
Henry S Chen, M.D
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1093793101
Verified facts
What the public records show
CMS Open Payments records show Henry S Chen, M.D received $3,500.67 in general payments during 2025 across 149 reported records.
AstraZeneca Pharmaceuticals LP accounted for 13.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 41 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Horizant, Jardiance, Linzess, Otezla, Ozempic, Prolia, Rexulti, Rybelsus, Trelegy Ellipta, Trintellix, Verquvo.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 482 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Otezla by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 460 claims for Farxiga by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBI as an associated drug or biological on 1140 records involving 805 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Edarbi by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBYCLOR as an associated drug or biological on 283 records involving 215 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Edarbyclor by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported HORIZANT as an associated drug or biological on 2733 records involving 1696 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Horizant by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 243 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synjardy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 243 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rexulti by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Verquvo by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trulance by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $486.45 | 13.9% | 23 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $310.86 | 8.9% | 14 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $310.74 | 8.9% | 12 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $263.57 | 7.5% | 15 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $240.31 | 6.9% | 12 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $220.02 | 6.3% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $200.98 | 5.7% | 9 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $194.83 | 5.6% | 12 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $193.70 | 5.5% | 5 | 2025 |
| Cleerly, Inc. | Unresolved — no canonical attribution shown | $188.17 | 5.4% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $175.79 | 5.0% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $150.56 | 4.3% | 6 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $120.05 | 3.4% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $74.67 | 2.1% | 4 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $67.53 | 1.9% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $47.66 | 1.4% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $45.99 | 1.3% | 2 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $40.19 | 1.1% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $39.86 | 1.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.89 | 1.0% | 2 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $27.90 | 0.8% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $25.45 | 0.7% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $23.20 | 0.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.30 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,500.67 | 149 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $228.76 | 10 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $202.52 | 10 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $198.22 | 9 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $194.83 | 12 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $189.96 | 9 | 2025 |
Source payment records
|
|||||
| Cleerly Ischemia Normalized: cleerly ischemia |
Device | Cleerly, Inc. | $188.17 | 1 | 2025 |
Source payment records
|
|||||
| Cleerly Labs Normalized: cleerly labs |
Device | Cleerly, Inc. | $188.17 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $185.26 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $175.79 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $143.16 | 6 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $143.16 | 6 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $143.16 | 6 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $142.56 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $141.60 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $141.60 | 9 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $132.23 | 6 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $112.64 | 5 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $98.61 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $97.87 | 5 | 2025 |
Source payment records
|
|||||
| ALVESCO Normalized: alvesco |
Drug | Azurity Pharmaceuticals, Inc. | $97.75 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $73.08 | 3 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $67.53 | 3 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $65.79 | 3 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $47.66 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $47.55 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $45.99 | 2 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $40.19 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $39.86 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $34.15 | 2 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $27.90 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $25.45 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $22.89 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $21.44 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.69 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $19.41 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.50 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.30 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.30 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.48 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $15.48 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $10.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 67 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 159 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 460 | exact normalized | Medicare Part D |
| HORIZANT horizant |
2025 | Horizant | 2024 | 101 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 243 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 37 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 112 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 127 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 46 | exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
67 | 21 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
482 | 146 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
37 | 27 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
460 | 139 |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBI open payments reported associated product |
CMS Open Payments — General Payments 1140 supporting records · 805 recipient NPIs · example record 1242666830 |
Edarbi · 2024 Exact normalized brand match · 1 Part D row |
159 | 43 |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBYCLOR open payments reported associated product |
CMS Open Payments — General Payments 283 supporting records · 215 recipient NPIs · example record 1242666846 |
Edarbyclor · 2024 Exact normalized brand match · 1 Part D row |
75 | 20 |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | HORIZANT open payments reported associated product |
CMS Open Payments — General Payments 2733 supporting records · 1696 recipient NPIs · example record 1242666828 |
Horizant · 2024 Exact normalized brand match · 1 Part D row |
101 | 30 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
243 | 69 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
94 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
127 | 47 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
243 | 69 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
66 | 23 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
112 | 36 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
159 | 61 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
46 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1534 | 484 |
| Losartan Potassium | Losartan Potassium | 1379 | 476 |
| Atorvastatin Calcium | Atorvastatin Calcium | 941 | 359 |
| Raloxifene Hcl | Raloxifene Hcl | 820 | 238 |
| Montelukast Sodium | Montelukast Sodium | 652 | 221 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 652 | 241 |
| Vascepa | Icosapent Ethyl | 607 | 140 |
| Carvedilol | Carvedilol | 589 | 194 |
| Tamsulosin Hcl | Tamsulosin Hcl | 555 | 165 |
| Metformin Hcl | Metformin Hcl | 506 | 173 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 495 | 137 |
| Synthroid | Levothyroxine Sodium | 482 | 146 |
| Donepezil Hcl | Donepezil Hcl | 475 | 166 |
| Farxiga | Dapagliflozin Propanediol | 460 | 139 |
| Ammonium Lactate | Ammonium Lactate | 439 | 163 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 435 | 137 |
| Allopurinol | Allopurinol | 411 | 131 |
| Metoprolol Succinate | Metoprolol Succinate | 369 | 122 |
| Zolpidem Tartrate | Zolpidem Tartrate | 347 | 112 |
| Sucralfate | Sucralfate | 335 | 124 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 330 | 120 |
| Memantine Hcl | Memantine Hcl | 291 | 82 |
| Diclofenac Epolamine | Diclofenac Epolamine | 254 | 74 |
| Clobetasol Propionate | Clobetasol Propionate | 251 | 107 |
| Jardiance | Empagliflozin | 243 | 69 |
| Atenolol | Atenolol | 242 | 75 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 241 | 79 |
| Fluocinonide | Fluocinonide | 235 | 88 |
| Finasteride | Finasteride | 220 | 73 |
| Valsartan | Valsartan | 192 | 69 |
| Levothyroxine Sodium | Levothyroxine Sodium | 191 | 80 |
| Meloxicam | Meloxicam | 190 | 104 |
| Sertraline Hcl | Sertraline Hcl | 183 | 58 |
| Diclofenac Sodium | Diclofenac Sodium | 167 | 59 |
| Celecoxib | Celecoxib | 166 | 59 |
| Januvia | Sitagliptin Phosphate | 162 | 50 |
| Edarbi | Azilsartan Medoxomil | 159 | 43 |
| Eliquis | Apixaban | 159 | 61 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 153 | 49 |
| Xarelto | Rivaroxaban | 153 | 41 |
| Hydralazine Hcl | Hydralazine Hcl | 149 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 147 | 59 |
| Metoprolol Tartrate | Metoprolol Tartrate | 143 | 53 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 136 | 41 |
| Fluoxetine Hcl | Fluoxetine Hcl | 136 | 38 |
| Hydrocortisone | Hydrocortisone | 129 | 44 |
| Lidocaine | Lidocaine | 128 | 45 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 128 | 44 |
| Entresto | Sacubitril/Valsartan | 127 | 38 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 127 | 47 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 123 | 40 |
| Rybelsus | Semaglutide | 112 | 36 |
| Lisinopril | Lisinopril | 110 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 107 | 37 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 106 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 105 | 35 |
| Horizant | Gabapentin Enacarbil | 101 | 30 |
| Rivastigmine | Rivastigmine | 99 | 29 |
| Vemlidy | Tenofovir Alafenamide | 94 | 20 |
| Dapagliflozin | Dapagliflozin Propanediol | 90 | 26 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 84 | 30 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 83 | 26 |
| Megestrol Acetate | Megestrol Acetate | 82 | 60 |
| Olanzapine | Olanzapine | 80 | 25 |
| Colchicine | Colchicine | 79 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 78 | 28 |
| Icosapent Ethyl | Icosapent Ethyl | 77 | 32 |
| Dicyclomine Hcl | Dicyclomine Hcl | 76 | 64 |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 75 | 20 |
| Simvastatin | Simvastatin | 74 | 29 |
| Fluocinonide-E | Fluocinonide/Emollient Base | 73 | 32 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 73 | 22 |
| Alendronate Sodium | Alendronate Sodium | 70 | 31 |
| Gabapentin | Gabapentin | 70 | 22 |
| Jentadueto | Linagliptin/Metformin Hcl | 70 | 20 |
| Myrbetriq | Mirabegron | 68 | 16 |
| Azithromycin | Azithromycin | 67 | 61 |
| Creon | Lipase/Protease/Amylase | 67 | 21 |
| Meclizine Hcl | Meclizine Hcl | 66 | 62 |
| Trulicity | Dulaglutide | 66 | 23 |
| Progesterone | Progesterone, Micronized | 63 | 23 |
| Tradjenta | Linagliptin | 61 | 17 |
| Clonidine | Clonidine | 59 | 15 |
| Azelastine Hcl | Azelastine Hcl | 58 | 22 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 58 | 12 |
| Cilostazol | Cilostazol | 55 | 17 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 54 | 16 |
| Prednisone | Prednisone | 54 | 43 |
| Dutasteride | Dutasteride | 53 | 14 |
| Ranolazine Er | Ranolazine | 50 | 18 |
| Telmisartan | Telmisartan | 50 | 14 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 49 | 18 |
| Ciclopirox | Ciclopirox | 48 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 48 | 15 |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 48 | 16 |
| Alcohol Pads | Alcohol Antiseptic Pads | 47 | 14 |
| Procto-Med Hc | Hydrocortisone | 47 | 22 |
| Trintellix | Vortioxetine Hydrobromide | 46 | 14 |
| Trazodone Hcl | Trazodone Hcl | 45 | 17 |
| Nebivolol Hcl | Nebivolol Hcl | 44 | 14 |
| Nifedipine Er | Nifedipine | 44 | 16 |
| Folic Acid | Folic Acid | 43 | 18 |
| Bepotastine Besilate | Bepotastine Besilate | 41 | 17 |
| Trulance | Plecanatide | 41 | suppressed |
| Clobetasol Emollient | Clobetasol Propionate/Emoll | 40 | 17 |
| Enalapril Maleate | Enalapril Maleate | 40 | 11 |
| Levetiracetam | Levetiracetam | 39 | 12 |
| Furosemide | Furosemide | 38 | 31 |
| Glipizide Er | Glipizide | 38 | 17 |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 37 | 14 |
| Prolia | Denosumab | 37 | 27 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 36 | 15 |
| Estradiol | Estradiol | 35 | 17 |
| Brilinta | Ticagrelor | 33 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 33 | 12 |
| Spironolactone | Spironolactone | 33 | 13 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 32 | 14 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 32 | suppressed |
| Calcitriol | Calcitriol | 31 | suppressed |
| Febuxostat | Febuxostat | 31 | suppressed |
| Methotrexate | Methotrexate Sodium | 31 | suppressed |
| Linzess | Linaclotide | 29 | suppressed |
| Mirtazapine | Mirtazapine | 29 | 12 |
| Propylthiouracil | Propylthiouracil | 29 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 28 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 28 | suppressed |
| Verquvo | Vericiguat | 27 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 26 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 25 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 25 | 13 |
| Labetalol Hcl | Labetalol Hcl | 25 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 25 | suppressed |
| Nitroglycerin | Nitroglycerin | 25 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 24 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Digoxin | Digoxin | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | 21 |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Methimazole | Methimazole | 22 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 17 |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 19 | suppressed |
| Haloperidol | Haloperidol | 19 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 18 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 17 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 17 | suppressed |
| Rexulti | Brexpiprazole | 17 | suppressed |
| Alprazolam | Alprazolam | 16 | 12 |
| Otezla | Apremilast | 16 | suppressed |
| Ozempic | Semaglutide | 16 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 16 | suppressed |
| Proctozone-Hc | Hydrocortisone | 15 | suppressed |
| Tacrolimus | Tacrolimus | 15 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 14 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Famotidine | Famotidine | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | 12 |
| Single Use Swab | Alcohol Antiseptic Pads | 12 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Nexletol | Bempedoic Acid | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,500.67 · 149 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, ACCRUFER, AIRSUPRA, ALVESCO, AREXVY, Arikayce, Auvelity, BREZTRI, Brinsupri, CAPVAXIVE, COLLAGENASE SANTYL, COMIRNATY, CREON, Cleerly Ischemia, Cleerly Labs, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, GARDASIL 9, HORIZANT, JARDIANCE, LINZESS, Leqembi, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, PROLIA, PYRUKYND, REXULTI, Rybelsus, TRELEGY ELLIPTA, TRINTELLIX, VERQUVO, Vest Therapy Und, Wegovy, XIFAXAN, ZEPBOUND | 24 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error